Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer

NCT02664077 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT02664077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02664077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2016
Completion date
October 31, 2019
Enrollment
34 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii (iiib or iiic) colon cancer